TrialJournal for immunotherapy of cancer2026

Prolonged survival after systemic immune reactivation by aglatimagene besadenovec plus valacyclovir in immune checkpoint inhibitor-refractory non-small cell lung cancer.

Charu Aggarwal et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.